VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
MedTech & Diagnostics

DaVita Executive Compensation (FY25)

DVA · Denver, CO · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Javier Rodriguez
Latest say-on-pay support
=
June 4, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on DaVita

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 4, 2026Latest filing (8-K): June 8, 2026
16 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
DaVita brief$500Get the executive brief
Velarion Intel, one year, every company
330 figures on this page: 319 cited to the filing that reported them, 11 calculated from figures it prints. See the citations

More on DaVita

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Javier Rodriguez: $21,807,489 → $18,210,597 (16.5% lower)
Say-on-pay support: 94.4% → 98.5% (4.1 points higher)
CEO pay ratio: 299:1 → 254:1 (15.1% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is DaVita's chief executive and what were they paid?
Javier Rodriguez, Chief Executive Officer, received $18,210,597 in total compensation for fiscal 2025. Rodriguez's total was 16.5% lower than the $21,807,489 reported for fiscal 2024.
What was DaVita's say-on-pay result?
The say-on-pay proposal drew 98.5% of votes cast for or against in favor at the meeting held June 4, 2026 for fiscal 2025.
Which companies are in DaVita's peer group?
The disclosed peer group includes Avantor, Baxter International, Centene, Dentsply Sirona and Encompass Health, among others.
What is DaVita's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 254:1, against median employee compensation of $71,839.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Joel Ackerman
Chief Financial Officer
◇—◇◇◇—◇◇
Kathleen Waters
Chief Legal Officer
◇—◇◇◇—◇◇
Javier Rodriguez
Chief Executive Officer
◇———◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Staffieri
Chief Operating Officer, DaVita Kidney Care
◇—◇—◇—◇◇
Joel Ackerman
Chief Financial Officer and Treasurer
◇—◇—◇—◇◇
Javier Rodriguez
Chief Executive Officer
◇———◇—◇◇
Kathleen Waters
Chief Legal and Public Affairs Officer
◇—◇—◇—◇◇
James Hearty
Chief Compliance Officer
◇—◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Javier J. Rodriguez
Chief Executive Officer
◇—◇—◇—◇◇
Michael D. Staffieri
Chief Operating Officer Emeritus
Departed during or after this year
◇—◇—◇—◇◇
Joel Ackerman
Chief Financial Officer and Treasurer
◇—◇—◇—◇◇
David P. Maughan
Chief Operating Officer, DaVita Kidney Care
◇—◇—◇—◇◇
Kathleen A. Waters
Chief Legal and Public Affairs Officer
◇—◇—◇—◇◇
James O. Hearty
Chief Compliance Officer
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Javier Rodriguez
Chief Executive Officer
◇—◇◇◇—◇◇
Joel Ackerman
Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
David Maughan
Chief Operating Officer, DaVita Kidney Care
◇—◇◇◇—◇◇
Kathleen Waters
Chief Legal and Public Affairs Officer
◇—◇◇◇—◇◇
James Hearty
Chief Compliance Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
David P. MaughanRSU◇——◇——◇
David P. MaughanPSU◇◇◇—◇—◇
David P. MaughanOPTION◇——◇—◇◇
James O. HeartyPSU◇◇◇—◇—◇
James O. HeartyRSU◇——◇——◇
James O. HeartyOPTION◇——◇—◇◇
Javier RodriguezPSU◇◇◇—◇—◇
Javier RodriguezRSU◇——◇——◇
Javier RodriguezOPTION◇——◇—◇◇
Joel AckermanPSU◇◇◇—◇—◇
Joel AckermanRSU◇——◇——◇
Joel AckermanOPTION◇——◇—◇◇
Kathleen A. WatersPSU◇◇◇—◇—◇
Kathleen A. WatersRSU◇——◇——◇
Kathleen A. WatersOPTION◇——◇—◇◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Javier RodriguezRSU◇◇——
RSU◇◇——
Option◇—◇3/15/2030
RSU◇◇——
RSU◇◇——
Joel AckermanRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/15/2027
Option◇—◇3/15/2030
RSU◇◇——
RSU◇◇——
RSU◇◇——
Kathleen WatersRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/15/2030
Option◇—◇3/15/2027
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
David MaughanRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/15/2030
RSU◇◇——
RSU◇◇——
James HeartyRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/15/2030
Option◇—◇3/15/2027
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
David Maughan
Chief Operating Officer, Kidney Care · Employment agreement · dated September 15, 2024
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Change-in-control base◇
Benefits continuation on change in control◇
Excise tax treatment◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Pamela M. Arway
Board chair
◇◇————◇
Barbara J. Desoer
◇◇————◇
Gregory J. Moore, M.D., Ph.D
◇◇————◇
Phyllis R. Yale
◇◇————◇
Jason M. Hollar
◇◇————◇
Wendy L. Schoppert
◇◇————◇
Adam H. Schechter
◇◇————◇
Dennis W. Pullin
◇◇————◇
Charles G. Berg
◇◇————◇
Javier J. Rodriguez served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇
Committee meeting fee◇
Equity is delivered as Dsi.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Avantor AVTR
  • Baxter International BAX
  • Centene CNC
  • Dentsply Sirona XRAY
  • Encompass Health EHC
  • HCA Healthcare HCA
  • Henry Schein HSIC
  • Hologic HOLX
  • IQVIA Holdings IQV
  • Labcorp Holdings Inc. LH
  • Molina Healthcare MOH
  • Quest Diagnostics DGX
  • Revvity RVTY
  • Select Medical Holdings SEM
  • Tenet Healthcare THC
  • Universal Health Services UHS
  • Zimmer Biomet Holdings ZBH

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 4, 2026=◇◇◇
2024June 5, 2025=◇◇◇
2023June 6, 2024=◇◇◇
2022June 6, 2023=◇◇◇
2021June 9, 2022=◇◇◇
2020June 10, 2021=◇◇◇
2019June 11, 2020=◇◇◇
2018June 17, 2019=◇◇◇
2017June 18, 2018=◇◇◇
2016June 16, 2017=◇◇◇
2015June 20, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Javier Rodriguez (Chief Executive Officer), FY2025 total compensation $18,210,597 (base salary $1,500,000) [exec_comp, SEC accession 0000927066-26-000053, filed 2026-04-22]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when DaVita files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact DaVita disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where DaVita sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether DaVita's disclosed peer group is defensible, who names DaVita back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
330 figures on this page: 319 cited to the filing that reported them, 11 calculated from figures it prints.
319 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001206774-26-000316
  2. 0000927066-26-000053
    2025 DIRECTOR COMPENSATION TABLE · 2025 Summary Compensation Table · CEO Pay Ratio · Grants of Plan-Based Awards Table · and 1 more section
  3. 0000927066-25-000107
  4. 0000927066-25-000076
    2024 Summary Compensation Table
  5. 0001206774-24-000897
    EX-10.1
  6. 0000927066-24-000115
  7. 0000927066-24-000078
    2023 Summary Compensation Table · Compensation of Directors
  8. 0000927066-23-000152
  9. 0000927066-23-000088
    Summary Compensation Table
  10. 0000927066-22-000121
  11. 0000927066-21-000127
  12. 0000927066-20-000148
  13. 0000927066-19-000116
  14. 0000927066-18-000135
  15. 0000927066-17-000024
  16. 0001193125-16-631163
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “DaVita executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/DVA (accessed 2026).
Short form: data: Velarion

The paid brief for DaVita

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Get the executive briefGet the board briefNo account needed.
16 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about DaVita and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers DaVita discloses

The companies named in DVA's own disclosed peer group.

AvantorBaxter InternationalCenteneDentsply SironaEncompass HealthHCA HealthcareHenry ScheinHologicIQVIA HoldingsLabcorp Holdings Inc.Molina HealthcareQuest DiagnosticsRevvitySelect Medical HoldingsTenet HealthcareUniversal Health ServicesZimmer Biomet Holdings

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy